Gardner J P, Frolov I, Perri S, Ji Y, MacKichan M L, zur Megede J, Chen M, Belli B A, Driver D A, Sherrill S, Greer C E, Otten G R, Barnett S W, Liu M A, Dubensky T W, Polo J M
Vaccines & Gene Therapy, Chiron Corporation, Emeryville, California 94608, USA.
J Virol. 2000 Dec;74(24):11849-57. doi: 10.1128/jvi.74.24.11849-11857.2000.
The ability to target antigen-presenting cells with vectors encoding desired antigens holds the promise of potent prophylactic and therapeutic vaccines for infectious diseases and cancer. Toward this goal, we derived variants of the prototype alphavirus, Sindbis virus (SIN), with differential abilities to infect human dendritic cells. Cloning and sequencing of the SIN variant genomes revealed that the genetic determinant for human dendritic cell (DC) tropism mapped to a single amino acid substitution at residue 160 of the envelope glycoprotein E2. Packaging of SIN replicon vectors with the E2 glycoprotein from a DC-tropic variant conferred a similar ability to efficiently infect immature human DC, whereupon those DC were observed to undergo rapid activation and maturation. The SIN replicon particles infected skin-resident mouse DC in vivo, which subsequently migrated to the draining lymph nodes and upregulated cell surface expression of major histocompatibility complex and costimulatory molecules. Furthermore, SIN replicon particles encoding human immunodeficiency virus type 1 p55(Gag) elicited robust Gag-specific T-cell responses in vitro and in vivo, demonstrating that infected DC maintained their ability to process and present replicon-encoded antigen. Interestingly, human and mouse DC were differentially infected by selected SIN variants, suggesting differences in receptor expression between human and murine DC. Taken together, these data illustrate the tremendous potential of using a directed approach in generating alphavirus vaccine vectors that target and activate antigen-presenting cells, resulting in robust antigen-specific immune responses.
用编码所需抗原的载体靶向抗原呈递细胞的能力为传染病和癌症的有效预防性和治疗性疫苗带来了希望。为了实现这一目标,我们获得了原型甲病毒辛德毕斯病毒(SIN)的变体,它们感染人类树突状细胞的能力各不相同。SIN变体基因组的克隆和测序表明,人类树突状细胞(DC)嗜性的遗传决定因素映射到包膜糖蛋白E2第160位残基的单个氨基酸取代。用来自DC嗜性变体的E2糖蛋白包装SIN复制子载体赋予了类似的有效感染未成熟人类DC的能力,随后观察到这些DC经历快速激活和成熟。SIN复制子颗粒在体内感染皮肤驻留小鼠DC,这些DC随后迁移至引流淋巴结并上调主要组织相容性复合体和共刺激分子的细胞表面表达。此外,编码1型人类免疫缺陷病毒p55(Gag)的SIN复制子颗粒在体外和体内引发了强烈的Gag特异性T细胞反应,表明受感染的DC保持了处理和呈递复制子编码抗原的能力。有趣的是,人类和小鼠DC被选定的SIN变体不同程度地感染,这表明人类和小鼠DC之间受体表达存在差异。综上所述,这些数据说明了采用定向方法生成靶向并激活抗原呈递细胞的甲病毒疫苗载体的巨大潜力,从而产生强烈的抗原特异性免疫反应。